KA Kineta Bio Year-over-year net earnings per share growth for the last 12 months
Kineta, Inc. is fighting to maintain its scientific potential amid acute funding shortages and intense competition. Simultaneously, the company adheres to bioethical norms and environmental production standards. The quarterly EPS growth confirms the current trend, where the metric is held at 0.00. Currently, the business's financial stability relies exclusively on external financing and grants due to a lack of recurring revenue.
Metric breakdowns and analytics for Kineta Corp (KA)
- market value and analyst target forecast:
- market capitalization data:
- book capitalization indicators:
- debt and liquidity data:
Total Debt to Equity Ratio Kineta, Inc.|KA - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Kineta, Inc.|KA - Company Cumulative Indebtedness|Debts to Book Capitalization Kineta Bio|KA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Kineta|Quick Liquidity kinetabio.com
- earnings and market multiples details:
KA - Final Profit|Projected Future Earnings Kineta, Inc.|KA - P/E Multiple|Future Price to Earnings Kineta Bio|KA - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Kineta Bio|KA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Kineta|KA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth kinetabio.com|KA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Kineta, Inc.
Fundamental company valuation:Kineta - KA
Kineta, Inc. focuses on developing breakthrough immuno-oncology drugs for the treatment of resistant forms of cancer by targeting the VISTA pathway. The quarterly EPS growth trajectory, stripped of market noise through daily recalculation, measures the real dynamics of net income per share, allowing for an assessment of the business's financial stability and the determination of the fair value of capital amid a sideways trend.
Who Kineta, Inc. competes with
ImmunityBio (IBRX) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Immunocore Holdings|Year-over-year net earnings per share growth for the last 12 months JANX|Quarterly EPS earnings growth Arcus Corp|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|tangotx.com - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Iovance Biotherapeutics, Inc. IOVA|Immatics NV (IMTX) - Earnings per share growth in annualized terms for the last twelve months|XNCR: Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Compass Therapeutics Corp (CMPX)|REPL (Replimune Group, Inc.) - Year-over-year net earnings per share growth for the last 12 months|LYEL: Year-over-year earnings per share growth rate for the last twelve months|IPHA (Innate Pharma) - Quarterly EPS earnings growth|PYXS: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CGEN|IOBT - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Sutro Biopharma, Inc. STRO|Year-over-year earnings per one share growth for the last 12 months INKT|Werewolf - Quarterly EPS earnings growth|IMMX - Quarterly EPS earnings growth|ALX Oncology (ALXO) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months CUE (Cue Biopharma Inc.)|Year-over-year net earnings per share growth for the last 12 months PDSB|Earnings per share growth in annualized terms for the last twelve months Sonnet BioTherapeutics Holdings Inc. SONN|Year-over-year earnings per share growth for the last twelve months MAIA Biotechnology, Inc. (MAIA)|Quarterly EPS earnings growth Liminatus Pharma Inc. (LIMN)|Quarterly EPS earnings growth LVTX (LAVA Therapeutics)|Year-over-year net earnings per share change for the last twelve months NextCure Corporation (NXTC)|LPTX - Year-over-year earnings per share growth for the last twelve months|INTS (Intensity Therapeutics) - Year-over-year earnings per share growth for the last 12 months|SNSE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Theriva Biologics Inc (TOVX)|Year-over-year net earnings per share growth for the last 12 months GRTS|NEXI (NexImmune Corporation) - Year-over-year earnings per share growth rate for the last twelve months|Quarterly EPS earnings growth TSBX|Quarterly EPS earnings growth vaccinex.com (VCNX)|Harpoon Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months
